Sage/Biogen See Big Potential Market For Zuranolone In PPD

SKYLARK Meets Primary, Key Secondary Endpoints

 
• By Alaric DeArment
  
Sage and Biogen announced results of the Phase III SKYLARK trial of zuranolone in postpartum depression • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business